Evidence map›Paper›PMID 31664946›Full record

ArticleBMC cancer2019

Clinical significance of serum PSA in breast cancer patients.

Toru Hanamura, Koichi Ohno, Shinya Hokibara, Hideki Murasawa, Toshitsugu Nakamura, Hidehiko Watanabe, Machiko Kaizuka, Shinji Sawano, Hiroshi Koyama, Ken-Ichi Ito

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toru HanamuraDepartment of Breast and Endocrine Surgery, Suwa Red Cross Hospital, 5-11-50, Kogan-dori, Suwa, Nagano, 392-8510, Japan. hanamuratooru@hotmail.co.jp.ORCID http://orcid.org/0000-0002-6934-8588
Koichi OhnoDepartment of Breast and Endocrine Surgery, Suwa Red Cross Hospital, 5-11-50, Kogan-dori, Suwa, Nagano, 392-8510, Japan.
Shinya HokibaraDepartment of Diagnostic Pathology, Suwa Red Cross Hospital, 5-11-50, Kogan-dori, Suwa, Nagano, 392-8510, Japan.
Hideki MurasawaDepartment of Laboratory Medicine, Suwa Red Cross Hospital, 5-11-50, Kogan-dori, Suwa, Nagano, 392-8510, Japan.
Toshitsugu NakamuraDepartment of Diagnostic Pathology, Suwa Red Cross Hospital, 5-11-50, Kogan-dori, Suwa, Nagano, 392-8510, Japan.
Hidehiko WatanabeMedical checkup Center, Suwa Red Cross Hospital, 5-11-50, Kogan-dori, Suwa, Nagano, 392-8510, Japan.
Machiko KaizukaDepartment of Surgery, Suwa Central Hospital, 4300, Tamagawa, Chino, Nagano, 391-8503, Japan.
Shinji SawanoDepartment of Surgery, Okaya City Hospital, 4-11-33, Hon-machi, Okaya, Nagano, 394-8512, Japan.
Hiroshi KoyamaKoyama Breast and Thyroid Clinic, 1-2557-1, Jonan, Suwa, Nagano, 392-0017, Japan.
Ken-Ichi ItoDivision of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent preclinical data suggest that androgen receptor (AR) signaling plays a significant role in subsets of breast cancer. Clinical trials testing AR-targeting therapies in breast cancer have been conducted. Assessment of AR-signal in breast cancer tissue maybe useful for treatment selections. Prostate specific antigen (PSA) is the product of an androgen-responsive gene. Serum PSA (sPSA) can be detected in women by a highly sensitive assay although the concentration is much lower than that observed in males. We investigated if sPSA reflects tumor biology, including AR signaling in breast cancer patients.

methodsIn this study, 132 healthy controls and 144 breast cancer patients were enrolled. sPSA was evaluated by the chemiluminescent enzyme immunoassay (CLEIA) method. Correlations between sPSA and the various clinicopathological factors were analyzed.

resultsIn post-menopausal state, sPSA detection rate was significantly higher in breast cancer patients compared with controls (27.4% vs 11.3%: p = 0.0090), but not in the whole cohort (29.2% vs 25.8%: p = 0.5265) or pre-menopausal subgroup (37.0% vs 42.6%: p = 0.6231). In post-menopausal breast cancer cases, higher sPSA value was associated with clinic-pathological factors including the expression of AR protein in primary legion. In a correlation analysis of quantitative data limited to post-menopausal metastatic breast cancer (MBC), sPSA was positively, albeit weakly correlated with clinic-pathological features including serum testosterone levels and AR positivity.

conclusionsOur data suggest that sPSA may reflect tumor biological properties including AR activity in post-menopausal breast cancer.

Indexed as

AdultAgedAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsCohort StudiesFemaleHumansImmunoenzyme TechniquesKallikreinsMiddle AgedPostmenopauseProstate-Specific AntigenReceptors, AndrogenTestosteroneAntineoplastic Agents, HormonalAR protein, humanBiomarkers, TumorKallikreinsKLK3 protein, humanProstate-Specific AntigenReceptors, AndrogenTestosteroneAndrogen receptorAndrogen signalBreast cancerPSA

Identifiers

PMID31664946
PMCPMC6819570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.